# Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma

> **NCT07674342** · NA · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 146 (estimated)

## Conditions studied

- Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **RADIATION:** Short-course Radiotherapy
- **DRUG:** Neoadjuvant Serplulimab and SOX Chemotherapy

## Key facts

- **NCT ID:** NCT07674342
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-06-30
- **Final completion:** 2031-06-30
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07674342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07674342, "Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07674342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*